Iquix

   
Google
 
Web NewDrugInformation.com

Iquix


Drug - Iquix
The trade name of the product as shown on the labeling.

Dosage - SOLUTION/DROPS; OPHTHALMIC
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Levofloxacin
Multiple ingredients are in alphabetical order.

Strength - 1.5%
The potency of the active ingredient(s), Levofloxacin. May repeat for multiple part products.

Applicant - SANTEN
The firm name holding legal responsibility for Iquix. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 021571
The FDA assigned number to Iquix. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Iquix. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Mar 1, 2004
The date Iquix was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Iquix. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Iquix is in. Format is RX, OTC, DISCN.

Applicant Full Name - Santen Inc
The full name of the firm holding legal responsibility for the new application of Iquix.

Iquix